Monte Rosa Therapeutics Inc (GLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2020 | 06-2020 | |
| Operating Expenses | 6,386 | 5,396 |
| Operating Income | -6,386 | -5,396 |
| Other Income | -172 | 32 |
| Pre-tax Income | -6,558 | -5,364 |
| Net Income Continuous | -6,558 | -5,364 |
| Net Income | $-6,558 | $-5,364 |
| EPS Basic Total Ops | -4.29 | -3.64 |
| EPS Basic Continuous Ops | -4.29 | -3.64 |
| EPS Diluted Total Ops | -4.29 | -3.64 |
| EPS Diluted Continuous Ops | -4.29 | -3.64 |
| EBITDA(a) | $-6,215 | $-5,396 |